CDT Equity (CDT) Net Income (2022 - 2026)
CDT Equity's (CDT) quarterly Net Income came in at -$4.1 million in Q1 2026, up 13.85% YoY from -$3.6 million in Q1 2025, and up 79.66% on a QoQ basis from -$19.9 million in Q4 2025.
CDT Equity (CDT) Net Income (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Net Income data on file, last reported at -$4.1 million in Q1 2026.
- Quarterly Net Income rose 13.85% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.2 million (down 43.06% YoY) and the FY2025 annual result came in at -$45.8 million, down 114.77% from the prior year.
- Net Income advanced to -$4.1 million in Q1 2026, from -$19.9 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $562808.0 in Q4 2022 to a low of -$42.9 million in Q1 2024.
- A 5-year average of -$6.3 million and a median of -$4.1 million in 2026 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income soared 147.44% — and 2024, when it sank 35808.29%.
- Tracing CDT's Net Income over 5 years: stood at $562808.0 in 2022, then sank by 266.84% to -$939000.0 in 2023, then plunged by 894.36% to -$9.3 million in 2024, then slumped by 113.56% to -$19.9 million in 2025, then soared by 79.66% to -$4.1 million in 2026.
- The last three Net Income figures came in at -$4.1 million (Q1 2026), -$19.9 million (Q4 2025), and -$7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 81.49 Mn |
| 10 | CDT Equity | 1.61 Mn | 1.61 Mn | - | -4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.54 Mn |
| Mar 31, 2026 | -4.06 Mn |
| Dec 31, 2025 | -19.94 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -6.04 Mn |
| Mar 31, 2025 | -4.71 Mn |
| Dec 31, 2024 | -9.34 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -5.47 Mn |
| Mar 31, 2024 | -42.95 Mn |
| Dec 31, 2023 | -939,000.00 |
| Sep 30, 2023 | -679,000.00 |
| Jun 30, 2023 | -343,711.00 |
| Mar 31, 2023 | 120,269.00 |
| Dec 31, 2022 | 562,808.00 |
| Sep 30, 2022 | 206,906.00 |
| Jun 30, 2022 | -117,539.00 |
| Mar 31, 2022 | -253,536.00 |